Webinar: Inside eXmoor’s Cell & Gene GMP Facility, Designed for Uncertainty
eXmoor Pharma's experts will present a case study of capabilities and lessons learned scaling its 65,000 foot GMP cell and gene therapy manufacturing center in the UK.
Regenerative Medicine News & Intelligence Hub
Cell & Gene Webinars
Webinar: Reimagining Gene-Modified T Cell Manufacturing – New Data on Integrating Isolation, Activation, Transduction, and Expansion in a Single Quantum Flex™ Workflow
Discover new data showcasing a streamlined approach to gene-modified T cell manufacturing that brings...
Webinar: Inside eXmoor’s Cell & Gene GMP Facility, Designed for Uncertainty
eXmoor Pharma's experts will present a case study of capabilities and lessons learned scaling...
Interviews & Articles
Guts & Glory: Both of Cynata’s iPSC Trials Flop, GVH Phase 2 and KOA Phase 3
Sad day for the industry, here's a summary of the CEO/Executive Chairman's readouts of...
Replacing Magnetic Separation with Buoyancy: A Closer Look at Bracco’s New Cell Selection Platform, BubbleGen™
Could a gentler, more scalable method improve how cells are isolated for advanced therapies?...
Interview: From Zero to One, How Terumo’s Ecosystem Blueprint Is Helping Scale Cell Therapies in Asia
Cell and gene therapies are advancing quickly, but the systems needed to deliver them...
Q&A – Inside iDEM, Mytos’ Automated Cell Therapy Manufacturing Platform
Pluripotent stem cell therapies are expensive, upwards of $500K–$1M per dose. Mytos has developed...
Interview: Veterinary Stem Cells – Gallant’s Quest for the First FDA-Approved MSC Therapy
Gallant is betting the future of veterinary regenerative medicine lies in scalable, well-characterized cell...
Chinese Study Reports Intranasal Muse Stem Cells Show Potential for Parkinson’s Treatment
Researchers report that intranasal Muse cells improved motor function and reduced neurodegeneration in a...
Study Finds Bone Marrow-Derived Stem Cells No Better Than Placebo for Chronic Low Back Pain
The trial found no significant difference in pain or function outcomes between bone marrow...
FDA’s New Regulatory Pathway May Forego RCTs for Ultra-Rare Conditions
Dr. Marty Makary and Dr. Vinay Prasad publish new article in New England Journal...
Interview: siRNA-Loaded Stem Cell Exosomes, Inside NurExone Biologic’s Spinal Cord Injury Candidate
NurExone's SCI candidate showed 100% gait recovery in rat models, and they're gearing up...
Potential Retraction Coming on Pivotal Phase 3 Stem Cell Trial for Heart Failure
What appeared to be a potential stem cell breakthrough is slowly being torn apart...
Inside Japan’s Regenerative Medicine Laws: JSRM Explains
What can the world learn from Japan’s regenerative medicine laws? We sat down with...
All The Latest
BrainStorm Cell Therapeutics Gearing Up for Phase 3b Trial of NurOwn, Its ALS Stem Cell Therapy, Submits IND Amendment
The amended IND application moves NurOwn® closer to initiation of the pivotal Phase 3b clinical trial for ALS patients.
Bayer’s BlueRock Therapeutics receives FDA Fast Track Designation for its iPSC OpCT-001 for primary photoreceptor diseases
This milestone positions BlueRock Therapeutics to accelerate clinical development of OpCT-001, aiming to restore vision in patients facing irreversible blindness.
Joseph Spine Institute Launches Adipose Stem Cell Spine Institute in Florida
Joseph Spine Institute launches its Center for Regenerative Spine Medicine in Tampa, offering minimally invasive stem cell therapies for chronic spinal conditions.
Japan startup applies for approval of iPS cell therapy for heart disease
Clinical trials involving eight patients showed improvements in symptoms and cardiac function.
Cellino and Matricelf Partnering to Scale Stem Cells for Spinal Cord Injury
Cellino has successfully manufactured and delivered patient-specific autologous induced pluripotent stem cell (iPSC) lines from four donors to Matricelf for spinal cord injury treatment.
Korea’s ‘JointStem’ Adipose Stem Cell Therapy gets FDA Breakthrough Therapy Designation for Osteoarthritis
Nature Cell Co., Ltd. announced that its cell therapy product, JointStem, has been granted Breakthrough Therapy Designation (BTD) by the U.S. FDA, marking a first for a Korean company in this field....
Garuda Therapeutics Nabs $50 Million Series A-1 Financing for Off-the-Shelf Blood Stem Cell Therapies
New funds aim to advance Garuda’s pipeline toward clinical trials, expand manufacturing capabilities, and support operational growth.
NASA awards $3.1M grant to continue studying stem cells aboard International Space Station
The National Stem Cell Foundation (NSCF) has received a $3.1 million grant from NASA to further its research on neurodegenerative diseases aboard the International Space Station (ISS). This funding will support additional...
MEDIPOST’s stem cell therapy regenerates stronger cartilage than microdrilling, clears path to US phase 3
Recent clinical data presented at the AAOS 2025 Annual Meeting in San Diego suggest that MEDIPOST's stem cell therapy, Cartistem, may offer a more effective treatment for severe knee osteoarthritis (OA) compared...
MIT engineers turn skin cells directly into neurons for cell therapy
MIT researchers have developed a new method to convert skin cells directly into neurons, bypassing the pluripotent stem cell stage in iPSC development. This technique, demonstrated in mouse cells, could potentially lead...
Stem Cell Expansion System: Terumo and Akron Bio Publish Results Showing Equivalency From Research to Manufacturing Grade Stem Cell Expansion Fibronectin
Terumo Blood and Cell Technologies (Terumo BCT) and Akron Bio say they've completed a collaborative study demonstrating equivalency between research-use-only (RUO) and Good Manufacturing Practices (GMP)-grade fibronectin for expanding mesenchymal stem cells...
Stem Cell and Exosome Trials are Hoping to Tackle Parkinson’s
In March this year, a ScienceDaily article reported that Mass General is pioneering a Phase 1 clinical trial advancing stem cell therapies for Parkinson's disease. The trial involves reprogramming patients' own stem...
AMSBIO unveils StemFit® for Differentiation, a GMP-grade medium for differentiating human induced pluripotent stem (hiPS) and embryonic stem (hES) cells
AMSBIO has introduced its GMP-grade StemFit® for Differentiation, a medium designed for the differentiation of human induced pluripotent stem (hiPS) and embryonic stem (hES) cells. This formulation, now compliant with Good Manufacturing...
Luxa Biotechnology Reports Significant Results in Dry Age-Related Macular Degeneration Stem Cell Trial
Luxa Biotechnology LLC has shared clinical data from its Phase 1/2a trial of RPESC-RPE-4W, a retinal pigment epithelium cell therapy for dry age-related macular degeneration (dry AMD). On the trial page, they...
Pharmaceutical giant GSK sees stem cells as useful for drug discovery and therapeutics
In a recent policy position statement, GlaxoSmithKline (GSK) mentioned that stem cell technology has its use cases in drug discovery, albeit it needs to be done in an ethical, safe way. Here's...
